Zifeng Yang1, Xingyu Feng1, Peng Zhang2, Tao Chen3, Haibo Qiu4, Yongjian Zhou5, Chunyan Du6, Xiaonan Yin7, Fang Pan8, Guoliang Zheng9, Xiufeng Liu10, Changming Huang5, Zhiwei Zhou4, Guoxin Li3, Kaixiong Tao11, Yong Li12. 1. Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, People's Republic of China. 2. Department of General Surgery, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China. 3. Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China. 4. Department of Gastric and Pancreatic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China. 5. Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, People's Republic of China. 6. Department of Gastric and Soft Tissue Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. 7. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. 8. Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, People's Republic of China. 9. Department of Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, 110042, People's Republic of China. 10. Department of Oncology, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA, Nanjing, 210000, People's Republic of China. 11. Department of General Surgery, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China. tao_kaixiong@163.com. 12. Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, People's Republic of China. yuan821007@126.com.
Abstract
BACKGROUND: The most common site of gastrointestinal stromal tumors (GISTs) is the stomach, and gastric GISTs (gGISTs) occur most often in elderly patients. However, the clinicopathological features, treatment patterns, and prognosis of elderly patients with gGISTs remain unclear. METHODS: We retrospectively collected clinicopathological and prognostic data for patients with primary gGISTs who underwent curative-intent resection at 10 medical centers in China from 1998 to 2015. RESULTS: Over the 18 years, 10 medical centers treated 1846 patients with primary gGISTs by curative-intent resection. The median age was 59 (range 18-91) years. The patients were classified into two groups according to age, namely an elderly group (≥ 65 years of age) and a nonelderly group (< 65 years of age). The elderly group had more comorbidities (40.7% vs 23.5%, p = 0.011), a higher rate of postoperative complications (14.4% vs 8.7%, p = 0.031), and a lower proportion of intermediate/high-risk patients who received adjuvant therapy (30.0% vs 66.8%, p = 0.001) than did the nonelderly group. Regarding pathological outcomes, a significant difference in tumor necrosis was observed between the two groups (p = 0.002), and more cases of tumor necrosis occurred in the elderly group than in the nonelderly group. Regarding postoperative recovery outcomes, no significant difference was observed between the two groups. Univariate analysis showed that age, postoperative complications, adjuvant therapy, tumor size, mitotic count, modified National Institutes of Health (NIH) risk category, and tumor necrosis were factors that affected disease-free survival (DFS). Multivariate analysis showed that modified NIH risk category was the only independent factor affecting DFS. The 5-year DFS rates in the nonelderly and elderly groups were 88.1% and 81.4%, respectively (p = 0.034), and the 5-year overall survival (OS) rates were 90.4% and 85.5% (p = 0.038), respectively. CONCLUSIONS: Currently, the treatment patterns for elderly patients with gGISTs remain the same as those for young patients with gGISTs. Elderly gGIST patients had more comorbidities and postoperative complications than did nonelderly gGIST patients, and fewer elderly gGIST patients received postoperative adjuvant therapy. Elderly gGIST patients also had a higher rate of tumor necrosis and worse DFS and OS than did young gGIST patients. Further exploration into the diagnosis and treatment patterns of elderly patients is therefore essential.
BACKGROUND: The most common site of gastrointestinal stromal tumors (GISTs) is the stomach, and gastric GISTs (gGISTs) occur most often in elderly patients. However, the clinicopathological features, treatment patterns, and prognosis of elderly patients with gGISTs remain unclear. METHODS: We retrospectively collected clinicopathological and prognostic data for patients with primary gGISTs who underwent curative-intent resection at 10 medical centers in China from 1998 to 2015. RESULTS: Over the 18 years, 10 medical centers treated 1846 patients with primary gGISTs by curative-intent resection. The median age was 59 (range 18-91) years. The patients were classified into two groups according to age, namely an elderly group (≥ 65 years of age) and a nonelderly group (< 65 years of age). The elderly group had more comorbidities (40.7% vs 23.5%, p = 0.011), a higher rate of postoperative complications (14.4% vs 8.7%, p = 0.031), and a lower proportion of intermediate/high-risk patients who received adjuvant therapy (30.0% vs 66.8%, p = 0.001) than did the nonelderly group. Regarding pathological outcomes, a significant difference in tumor necrosis was observed between the two groups (p = 0.002), and more cases of tumor necrosis occurred in the elderly group than in the nonelderly group. Regarding postoperative recovery outcomes, no significant difference was observed between the two groups. Univariate analysis showed that age, postoperative complications, adjuvant therapy, tumor size, mitotic count, modified National Institutes of Health (NIH) risk category, and tumor necrosis were factors that affected disease-free survival (DFS). Multivariate analysis showed that modified NIH risk category was the only independent factor affecting DFS. The 5-year DFS rates in the nonelderly and elderly groups were 88.1% and 81.4%, respectively (p = 0.034), and the 5-year overall survival (OS) rates were 90.4% and 85.5% (p = 0.038), respectively. CONCLUSIONS: Currently, the treatment patterns for elderly patients with gGISTs remain the same as those for young patients with gGISTs. Elderly gGIST patients had more comorbidities and postoperative complications than did nonelderly gGIST patients, and fewer elderly gGIST patients received postoperative adjuvant therapy. Elderly gGIST patients also had a higher rate of tumor necrosis and worse DFS and OS than did young gGIST patients. Further exploration into the diagnosis and treatment patterns of elderly patients is therefore essential.
Authors: Linda C Harlan; Jana Eisenstein; Maria C Russell; Jennifer L Stevens; Kenneth Cardona Journal: J Surg Oncol Date: 2015-05 Impact factor: 3.454
Authors: Anthony Paul Conley; Annie Guerin; Medha Sasane; Genevieve Gauthier; Frances Schwiep; Christopher Hunt Keir; Eric Q Wu Journal: J Gastrointest Cancer Date: 2014-12
Authors: Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Odd R Monge; Petri Bono; Raija Kallio; Aki Vehtari; Mika Leinonen; Thor Alvegård; Peter Reichardt Journal: JAMA Date: 2012-03-28 Impact factor: 56.272
Authors: Shomik Sengupta; Christine M Lohse; Bradley C Leibovich; Igor Frank; R Houston Thompson; W Scott Webster; Horst Zincke; Michael L Blute; John C Cheville; Eugene D Kwon Journal: Cancer Date: 2005-08-01 Impact factor: 6.860
Authors: Kjetil Søreide; Oddvar M Sandvik; Jon Arne Søreide; Vanja Giljaca; Andrea Jureckova; V Ramesh Bulusu Journal: Cancer Epidemiol Date: 2015-11-24 Impact factor: 2.984
Authors: Mee-Yon Cho; Jin Hee Sohn; Joon Mee Kim; Kyoung-Mee Kim; Young Su Park; Woo Ho Kim; Jin Sook Jung; Eun Sun Jung; So-Young Jin; Dae Young Kang; Jae Bok Park; Ho Sung Park; You Duck Choi; Sun Hee Sung; Young-Bae Kim; Hogeun Kim; Young-Kyung Bae; Miseon Kang; Hee Jin Chang; Yang Seok Chae; Hee Eun Lee; Do Youn Park; Youn Soo Lee; Yun Kyung Kang; Hye Kyung Kim; Hee-Kyung Chang; Soon Won Hong; Young Hee Choi; Okran Shin; MiJin Gu; Youn Wha Kim; Gwang Il Kim; Sei Jin Chang Journal: J Korean Med Sci Date: 2010-05-24 Impact factor: 2.153
Authors: N Hiraoka; Y Ino; S Sekine; H Tsuda; K Shimada; T Kosuge; J Zavada; M Yoshida; K Yamada; T Koyama; Y Kanai Journal: Br J Cancer Date: 2010-08-24 Impact factor: 7.640
Authors: Sheima Farag; Frits van Coevorden; Esther Sneekes; Dirk J Grunhagen; Anna K L Reyners; Pieter A Boonstra; Winette T van der Graaf; Hans J Gelderblom; Neeltje Steeghs Journal: Eur J Cancer Date: 2017-10-23 Impact factor: 9.162
Authors: Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ernest U Conrad; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Henry Koon; Joel Mayerson; Martin McCarter; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; Ivy A Petersen; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; William D Tap; Jeffrey D Wayne; Mary Anne Bergman; Jillian Scavone Journal: J Natl Compr Canc Netw Date: 2016-06 Impact factor: 11.908